Search - tctmd.com

Displaying 541 - 560 of 749

Sort: Relevancy | Date

News Daily News

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Caitlin E. Cox

January 30, 2013

News Daily News

ASCERT: Los Resultados a Largo Plazo Favorecen a la CABG sobre la PCI en el Tratamiento de la Enfermedad Multivaso

Yael L. Maxwell

January 29, 2013

News Daily News

ASCERT: Long-term Results Favor CABG Over PCI for Multivessel Disease

Yael L. Maxwell

January 29, 2013

News Daily News

Retrasar una Angiografía Completa hasta despues de una PCI Primaria Radial Reduce el Tiempo Puerta a Balón

January 22, 2013

Presentation Cell Therapy 2013

EXCELLENT Trial Design

Presenter: J?r?me Roncalli

January 22, 2013

News Daily News

Delaying Complete Angiography Until After Radial Primary PCI Cuts D2B Time

January 22, 2013

News Industry News

Abbott Initiates Clinical Trial of Absorb™ in the United States

January 07, 2013

News Industry News

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

January 02, 2013

News Daily News

Renal Denervation Shows Sustained BP Improvements at 1 Year

Jason Kahn

December 26, 2012

News Daily News

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Caitlin E. Cox

December 26, 2012

News Daily News

La Denervación Renal Confirma Mejoras Sostenidas de la Presión Arterial al cabo de 1 Año

Jason Kahn

December 26, 2012

News Daily News

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Caitlin E. Cox

December 26, 2012

News Daily News

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Jason Kahn

December 05, 2012

News Industry News

Edwards Lifesciences Receives Approval for PERIMOUNT Mitral Heart Valve in China

November 27, 2012

News Industry News

FDA Approves Medtronic Stent Graft for Aortic Transection Repair

November 12, 2012

News Industry News

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

October 25, 2012

News Industry News

Survival Benefit With Edwards SAPIEN Valve Widens Further at Three Years

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

October 24, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

October 24, 2012

Advertisement

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

ASCERT: Los Resultados a Largo Plazo Favorecen a la CABG sobre la PCI en el Tratamiento de la Enfermedad Multivaso

ASCERT: Long-term Results Favor CABG Over PCI for Multivessel Disease

Retrasar una Angiografía Completa hasta despues de una PCI Primaria Radial Reduce el Tiempo Puerta a Balón

EXCELLENT Trial Design

Delaying Complete Angiography Until After Radial Primary PCI Cuts D2B Time

Abbott Initiates Clinical Trial of Absorb™ in the United States

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

Renal Denervation Shows Sustained BP Improvements at 1 Year

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

La Denervación Renal Confirma Mejoras Sostenidas de la Presión Arterial al cabo de 1 Año

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Edwards Lifesciences Receives Approval for PERIMOUNT Mitral Heart Valve in China

FDA Approves Medtronic Stent Graft for Aortic Transection Repair

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

Survival Benefit With Edwards SAPIEN Valve Widens Further at Three Years

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content